Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Wednesday, April 15, 2020
Immunoprecise Antibodies announced has entered into a research license agreement with Janssen Research & Development.
read more
Immunoprecise Antibodies announced the opening of its 3,200 square foot antibody production laboratory at Vancouver Island Technology Park.
read more
ImmunoPrecise and LiteVax announced a preclinical study to analyze IPA's novel SARS-CoV-2 vaccine candidates, has been granted funding by TRANSVAC2.
read more
Tuesday, November 29, 2022
Immutep Limited has signed a Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer for a new Phase I clinical study in patients with urothelial cancer, called INSIGHT-005.
read more
Monday, September 23, 2019
Immutep will receive a milestone payment from GSK of £4 million related to the first patient being dosed in GSK’s Phase II clinical trial evaluating GSK2831781 for ulcerative colitis.
read more
Tuesday, December 29, 2020
Immutep has prioritized the recommencement of the process of scaling up the manufacturing of its lead product candidate eftilagimod alpha.
read more
Thursday, December 21, 2017
Impax Laboratories has entered into a definitive agreement to sell its manufacturing facility in Taiwan to Bora Pharmaceuticals.
read more
Impax Laboratories, Inc. announced that its Board of Directors has appointed Paul M. Bisaro as Impax's President and Chief Executive Officer and a member of the Company's Board, effective March 27, 2017. Mr. Bisaro will succeed J. Kevin Buchi, who ...
read more
Thursday, September 17, 2015
Impax Laboratories has announced that the FDA has approved generic Mestinon Timespan Tablets (pyridostigmine bromide extended release), 180 mg.
read more
Wednesday, February 08, 2017
Impel NeuroPharma, a Seattle-based clinical stage biotechnology company developing first-in-class intranasal drug treatments announced has entered into service agreements with Camargo Pharmaceutical Services, LLC ("Camargo").
read more
Wednesday, November 12, 2014
Implandata Ophthalmic Products GmbH (Implandata) an ophthalmic surgical product and e-Health start-up company announces the closing of a €3M Series B-Round. Born2Grow Venture Partners, a private fund based in Heilbronn/Germany joins in as new ...
read more
Wednesday, January 24, 2018
Imprimis announced its New Jersey FDA-registered outsourcing facility has been issued a DEA Manufacturer Controlled Substance Registration Certificate.
read more
Friday, February 17, 2017
Imprimis Pharmaceuticals has begun shipping its core sterile ophthalmic medications to select customers from its FDA-registered outsourcing facility without the need for a patient-specific prescription. Over the next few weeks Imprimis' flagship ...
read more
Imprimis Pharmaceuticals has filed for registration of its recently-constructed New Jersey facility with the U.S. Food and Drug Administration (FDA) as a 503B outsourcing facility. The state-of-the-art facility is expected to begin manufacturing as ...
read more
Imprimis Pharmaceuticals, a pharmaceutical company focused on the development and commercialization of proprietary and customizable drug formulations, announced that it has filed for registration of its ImprimisRx TX pharmacy, located in Allen, Texas...
read more